Insulins: upcoming discontinuations

Last Updated: 3 July 2026

Discontinuation Active

Some insulin products are being discontinued.

3 July 2026 | Update

Humalog and Humulin NPH will continue to be sold for longer. Humalog until end of July 2026 and Humulin NPH until end August 2026.

Educational resource for health care professionals

NZSSD has published an education resource giving an update on the availability and use of insulins in New Zealand.

Insulin therapy in diabetes: a clinical update [PDF] | NZSSD website(external link) (18 January 2026)

Affected products

The following products are being discontinued:

Brand	Presentation	Chemical	Pharmacode	Supply ends	Funding ends
PenMix 30	Inj human with neutral insulin 100 u per ml, 3 ml	Isophane insulin, insulin neutral	785733	October 2025 stock expired April 2026	1 May 2026
Humulin R	Inj human 100 u per ml, 10 ml vial	Insulin neutral	2703009	end February 2026	to be confirmed
Apidra	Inj 100 u per ml, 10 ml	Insulin glulisine	2317109	April 2026	to be confirmed
Humalog	Inj 100 u per ml, 10 ml vial	Insulin lispro	2702983	end July 2026	to be confirmed
Humulin NPH	Inj human 100 u per ml, 10 ml vial	Insulin isophane	2702940	end August 2026	to be confirmed
Humulin 30/70	Inj human with neutral insulin 100 u per ml, 10 ml vial	Insulin isophane with insulin neutral	2702975	end June 2026	to be confirmed
NovoMix 30 FlexPen	Inj 100 iu per ml, 3 ml prefilled pen	Insulin aspart with insulin aspart protamine	2404303	December 2026	to be confirmed
Actrapid Penfill	Inj human 100 u per ml, 3 ml	Insulin neutral	797138	End 2026	to be confirmed
Protaphane Penfill	Inj human 100 u per ml, 3 ml	Insulin isophane	797162	End 2026	to be confirmed

People who use these products

There are funded alternatives. You can continue to access funded insulin treatment. You will need to talk to your prescriber as soon as possible to discuss the best options for your clinical situation.

For health care professionals

There are a number of other fully funded insulin products that may be suitable alternatives for your patients.

NZSSD has published an education resource giving an update on the availability and use of insulins in New Zealand.

Insulin therapy in diabetes: a clinical update [PDF] | NZSSD website(external link) (18 January 2026)

PenMix 30

Any remaining stock of this product expires in April 2026. It will be delisted from 1 May 2026.

Apidra

Only the 10 ml inj is being discontinued. Stock of the 3 ml injection and disposable pen will remain available. Fewer than 30 people are currently getting the 10 ml injection vial size.

Schedule listings for insulin glulisine(external link)

Humalog, Humulin NPH, Humulin 30/70, Humulin R vials

Only the 10 ml vial versions of these products are being discontinued. The 3 ml penfill presentations remain available.

NovoMix 30 FlexPen

The Novo Nordisk will stop supplying the NovoMix 30 FlexPen in December 2026. We funded Ryzodeg which may be a suitable alternative to NovoMix 30.

Ryzodeg (biphasic insulin degludec + insulin aspart) monograph | NZ Formulary(external link)

Actrapid Penfill and Protaphane Penfill

The 3 ml penfill presentations are being discontinued. The 10 ml vial presentations remain available.

More information

We encourage health care professionals to discuss a safe transition to an alternative funded product based on your patient’s individual needs.

Schedule listings for short-acting insulin preparations(external link)

Schedule listings for intermediate-acting insulin preparations(external link)

Insulin information in the NZ Formulary(external link)

Background

The insulin products on this page are supplied by a range of companies. These companies are discontinuing supply of some of their products that aren't used much or have been superseded by other insulin products.

All information about insulin discontinuations have been put on one page to allow health care providers to see the full range of affected products.

Who to contact

If you have questions about this issue, email enquiry@pharmac.govt.nz

Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.